2009年11月26日 · It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in...

Because rituximab specifically targets CD20-expressing B cells and, based on reported B lymphocyte depletion and regeneration kinetics after its administration, monitoring the depletions of different B cell subsets to anticipate clinical RA relapse and initiate reinfusions as early as possible to ensure tight disease control warrants ...

Identification of B cell differentiation stages by means of a specific flow cytometry panel could improve monitoring of rituximab effects and enable non-responders to be distinguished from good responders. Keywords: B cells; Flow cytometry; Rituximab; T cells. Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody.

2008年2月14日 · Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes. In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing–remitting multiple...

It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes.

We utilized data from the Lupus Nephritis Assessment with Rituximab (LUNAR) study to characterize the variability of peripheral blood B cell depletion after rituximab and assess its association with complete response in patients with lupus nephritis. We analyzed 68 participants treated with rituximab.

B cell depletion with rituximab, a chimeric monoclonal antibody that selectively targets B cells by binding CD20, has been used off label in severe and resistant systemic lupus erythematosus (SLE) for over two decades. Several biological mechanisms limit the efficacy of rituximab, including immunolo …

2020年2月22日 · The efficacy of rituximab therapy in different immune-inflammatory disorders with or without B cell malignancies has been widely demonstrated and associated with depletion of B cells, evaluated by flow cytometric analysis of peripheral CD19 + B cells.

2021年11月30日 · Treatment with RTX leads to B cell depletion and therefore a reduced antibody formation as well as suppression of the B cell-T cell interaction (3). Previous assessments of the treatment of nephrotic syndrome have indicated a correlation between dose and application interval on the one hand and B cell reconstitution time and recurrence of ...

Our objective was to evaluate the contribution of monitoring B cell subset depletion after rituximab in patients with rheumatoid arthritis (RA) in order to guide reintroduction to forestall relapse. This prospective, monocentre study included all RA patients receiving two 1-g rituximab infusions at …